Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Eli Lilly reported adjusted earnings of $7.48 per share versus $6.26 expected and revenue of $24.40 billion versus $22.61 billion expected, sending shares up about 9% on Thursday.
- Eli Lilly raised its full-year revenue outlook to $91 billion–$92 billion from $85 billion–$87 billion, yet trimmed adjusted EPS guidance to $35–$36 because $4.57 per share of deal charges offset a $4.07 per share underlying profit increase at the midpoint.
- Mounjaro worldwide revenue jumped 65% to $10.72 billion, including about $5 billion in the U.S., beating StreetAccount estimates of $10.10 billion globally and $4.79 billion domestically, with sales outside the U.S. surging 93%.
- Zepbound revenue climbed 49% to $5.35 billion, beating the $5.09 billion analysts expected, even as Lilly's realized U.S. prices fell 7% — primarily on Zepbound — following the drug pricing deal with the Trump administration.
- Foundayo delivered $184 million since its April U.S. launch, short of the roughly $229 million analysts expected, though U.S. prescriptions and new patients doubled from the prior quarter and 4 in 10 patients starting an oral obesity medicine chose it; Lilly expects U.S. approval for Type 2 diabetes in the fourth quarter.
- Novo holds 36.6% of the U.S. obesity and diabetes market against Lilly's 63%, with CFO Lucas Montarces saying 7 of 10 U.S. injectable prescriptions were for a Lilly medicine and Lilly holding 58.4% share internationally.
- Medicare began covering GLP-1 drugs for weight loss in July under a temporary pilot program, with CEO Dave Ricks calling the early uptake "really working" while estimating only 3% to 10% of eligible U.S. patients currently access obesity care.
Why it matters: Lilly's revenue raise rests on volume, not price: U.S. volume rose 41% while realized prices fell 7%, and international prices dropped 29%. Novo's U.S. share sits at 36.6% against Lilly's 63%, and the $184 million Foundayo miss shows the pill front isn't yet a clean offset.
Ask SkimNews
